Selective Elimination of Host Cells Harboring Replication-Competent Human Immunodeficiency Virus Reservoirs: A Promising Therapeutic Strategy for HIV Cure
The persistent challenge of achieving a cure for HIV lies in the virus’s ability to integrate into the host genome and establish latent reservoirs that evade both immune detection and antiretroviral therapy (ART). Despite significant advancements in controlling viral replication, lifelong ART remains necessary to suppress HIV, as treatment interruption inevitably leads to viral rebound. Current strategies such as the “shock and kill” approach and the “block and lock” method have shown limited success, underscoring the need for novel therapeutic interventions. The Selective Elimination of Host Cells Capable of Producing HIV (SECH) emerges as a promising strategy to address these limitations by combining multiple mechanisms to eradicate replication-competent reservoirs while preventing new infections.
The SECH Concept
The SECH strategy aims to eliminate host cells harboring functional provirus through a multipronged approach involving latency reversal, apoptosis induction, autophagy inhibition, and prevention of new infections. This method distinguishes itself from previous strategies by synergistically targeting critical pathways to ensure the death of infected cells and block viral spread. In a groundbreaking study, Li et al. (2020) demonstrated the efficacy of a therapeutic cocktail comprising:
- Latency reversal agents (LRAs) such as ingenol-3,20-dibenzoate (IDB), which activate HIV transcription by stimulating protein kinase C (PKC) and nuclear factor kappa B (NF-κB) pathways.
- Pro-apoptotic agents like ABT-263, a Bcl-2 and Bcl-XL inhibitor, which overcomes HIV-induced anti-apoptotic signals.
- Autophagy inhibitors such as SAR405, which blocks Class III PI3-kinase (VPS34), disrupting cellular survival mechanisms exploited by HIV.
- Attachment inhibitors (e.g., BMS-663068) and integrase inhibitors (e.g., raltegravir) to prevent viral entry and integration into new host cells.
In murine models, this cocktail achieved functional cure in >50% of HIV-infected mice after 40 treatment cycles, with complete viral suppression and no rebound post-ART withdrawal. Notably, the addition of JQ1, a bromodomain inhibitor, increased the cure rate to 77%. These results highlight the potential of SECH to target both active and latent reservoirs effectively.
Mechanisms Underlying the SECH Strategy
1. Latency Reversal and Reservoir Activation
HIV latency is maintained through epigenetic silencing, repressive histone modifications, and limited availability of host transcription factors. LRAs counteract these mechanisms to reactivate proviral transcription. IDB, a PKC agonist, induces NF-κB signaling, driving HIV long terminal repeat (LTR)-mediated transcription. Other LRAs, including histone deacetylase inhibitors (HDACis) like vorinostat and BET inhibitors like JQ1, synergize to reverse latency in diverse reservoirs, including CD4+ T cells and macrophages. However, the heterogeneity of integration sites and viral subtypes necessitates combination therapies to achieve broad latency reversal.
2. Autophagy Inhibition
Autophagy, a cellular degradation process, is hijacked by HIV to support viral replication and evade immune detection. The virus manipulates autophagy via proteins like Nef, which binds Beclin-1 to inhibit autophagosome maturation. SAR405, a VPS34 inhibitor, disrupts autophagy initiation, sensitizing infected cells to apoptosis. Studies show that autophagy inhibition destabilizes HIV-infected cells, reducing viral replication and enhancing clearance. Other inhibitors, such as chloroquine and bafilomycin A1, block late-stage autophagy by increasing lysosomal pH, further compromising cell survival.
3. Apoptosis Induction in Reservoir Cells
HIV-infected cells evade apoptosis by upregulating anti-apoptotic proteins like Bcl-XL and Mcl-1. ABT-263 (navitoclax) counteracts these defenses by inhibiting Bcl-2 and Bcl-XL, triggering mitochondrial apoptosis. In vitro and in vivo studies demonstrate that combining ABT-263 with LRAs like IDB selectively kills HIV-infected CD4+ T cells while sparing uninfected cells. Benzolactam-related compounds, such as BL-V8-310, exemplify dual-function agents that reactivate latency and activate caspase-3, promoting targeted apoptosis.
4. Preventing New Infections
To avoid reseeding the reservoir, SECH incorporates attachment inhibitors (BMS-663068) and integrase strand transfer inhibitors (INSTIs). BMS-663068 blocks gp120-CD4 interactions, while INSTIs like dolutegravir and cabotegravir prevent viral DNA integration. Cabotegravir, a long-acting injectable INSTI, has shown sustained viral suppression in clinical trials, underscoring its role in maintaining remission post-SECH therapy.
Challenges and Considerations
Despite its promise, SECH faces significant hurdles:
- Heterogeneity of HIV Reservoirs: HIV subtypes and integration sites influence latency reversal efficacy. Non-B subtypes, which account for 88% of global infections, may exhibit differential LTR activity and drug responsiveness. Personalized approaches or pan-subtype LRAs are needed to address this variability.
- Off-Target Effects of Pro-Apoptotic Drugs: ABT-263 and similar agents may induce apoptosis in uninfected cells, risking toxicity. Strategies to sensitize infected cells—e.g., sequential administration of LRAs before apoptosis inducers—could enhance specificity.
- Immune System Limitations: CD8+ T cells and natural killer (NK) cells often fail to penetrate lymphoid follicles, where active replication occurs. Augmenting immune function with cytokines like IFN-α or IL-15 may improve reservoir clearance.
Conclusion
The SECH strategy represents a paradigm shift in HIV cure research by integrating latency reversal, apoptosis, autophagy inhibition, and infection blockade. Its success hinges on optimizing drug combinations to address viral diversity and reservoir complexity. Future directions include refining targeted delivery systems (e.g., nanoparticle-based therapies) and exploring biomarkers to monitor reservoir dynamics. By overcoming current limitations, SECH could transition from preclinical promise to clinical reality, offering a pathway to sustained HIV remission.
doi.org/10.1097/CM9.0000000000001797
Was this helpful?
0 / 0